|
1
|
Vatanasapt V, Sriamporn S and Vatanasapt
P: Cancer control in Thailand. Jpn J Clin Oncol. 32(Suppl):
S82–S91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sriamporn S, Pisani P, Pipitgool V,
Suwanrungruang K, Kamsa-ard S and Parkin DM: Prevalence of
Opisthorchisviverrini infection and incidence of cholangiocarcinoma
in Khon Kaen, Northeast Thailand. Trop Med Int Health. 9:588–594.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel T: Worldwide trends in mortality
from biliary tract malignancies. BMC Cancer. 2:102002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thamavit W, Bhamarapravati N, Sahaphong S,
Vajrasthira S and Angsubhakorn S: Effects of dimethylnitrosamine on
induction of cholangiocarcinoma in Opisthorchis viverrini-infected
Syrian golden hamsters. Cancer Res. 38:4634–4639. 1978.PubMed/NCBI
|
|
5
|
Thamavit W, Kongkanuntn R, Tiwawech D and
Moore MA: Level of Opisthorchis infestation and carcinogen
dose-dependence of cholangiocarcinoma induction in Syrian golden
hamsters. Virchows Arch B Cell Pathol Incl Mol Pathol. 54:52–58.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patel T: Cholangiocarcinoma. Nat Clin
Pract Gastroenterol Hepatol. 3:33–42. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patel T: Cholangiocarcinoma -
controversies and challenges. Nat Rev Gastroenterol Hepatol.
8:189–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thongprasert S: The role of chemotherapy
in cholangiocarcinoma. Ann Oncol. 16(Suppl 2): ii93–ii96. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patt YZ, Hassan MM, Lozano RD, Waugh KA,
Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, et
al: Phase II trial of cisplatin, interferon alpha-2b, doxorubicin,
and 5-fluorouracil for biliary tract cancer. Clin Cancer Res.
7:3375–3380. 2001.PubMed/NCBI
|
|
11
|
Lee MA, Woo IS, Kang JH, Hong YS and Lee
KS: Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in
advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol.
130:346–350. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sookprasert A, Chindaprasert J and
Wirasorn K: Systemic therapy for locally advanced and metastatic
cholangiocarcinoma. Asian Pac J Cancer Prev. 13(Suppl): S3–S6.
2012.
|
|
13
|
Choi CW, Choi IK, Seo JH, Kim BS, Kim JS,
Kim CD, Um SH, Kim JS and Kim YH: Effects of 5-fluorouracil and
leucovorin in the treatment of pancreatic-biliary tract
adenocarcinomas. Am J Clin Oncol. 23:425–428. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noordhuis P, Holwerda U, Van der Wilt CL,
Van Groeningen CJ, Smid K, Meijer S, Pinedo HM and Peters GJ:
5-Fluorouracil incorporation into RNA and DNA in relation to
thymidylate synthase inhibition of human colorectal cancers. Ann
Oncol. 15:1025–1032. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Namwat N, Amimanan P, Loilome W,
Jearanaikoon P, Sripa B, Bhudhisawasdi V and Tassaneeyakul W:
Characterization of 5-fluorouracil-resistant cholangiocarcinoma
cell lines. Chemotherapy. 54:343–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bourdon JC, Fernandes K, Murray-Zmijewski
F, Liu G, Diot A, Xirodimas DP, Saville MK and Lane DP: p53
isoforms can regulate p53 transcriptional activity. Genes Dev.
19:2122–2137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marcel V, Perrier S, Aoubala M, Ageorges
S, Groves MJ, Diot A, Fernandes K, Tauro S and Bourdon JC: Δ160p53
is a novel N-terminal p53 isoform encoded by Δ133p53 transcript.
FEBS Lett. 584:4463–4468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujita K, Mondal AM, Horikawa I, Nguyen
GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR,
et al: p53 isoforms Delta133p53 and p53beta are endogenous
regulators of replicative cellular senescence. Nat Cell Biol.
11:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu X: Tied up in loops: Positive and
negative autoregulation of p53. Cold Spring Harb Perspect Biol.
2:a0009842010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song W, Huo SW, Lü JJ, Liu Z, Fang XL, Jin
XB and Yuan MZ: Expression of p53 isoforms in renal cell carcinoma.
Chin Med J (Engl). 122:921–926. 2009.
|
|
22
|
Anensen N, Oyan AM, Bourdon JC, Kalland
KH, Bruserud O and Gjertsen BT: A distinct p53 protein isoform
signature reflects the onset of induction chemotherapy for acute
myeloid leukemia. Clin Cancer Res. 12:3985–3992. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hofstetter G, Berger A, Fiegl H, Slade N,
Zori A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G,
et al: Alternative splicing of p53 and p73: The novel p53 splice
variant p53delta is an independent prognostic marker in ovarian
cancer. Oncogene. 29:1997–2004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boldrup L, Bourdon JC, Coates PJ, Sjöström
B and Nylander K: Expression of p53 isoforms in squamous cell
carcinoma of the head and neck. Eur J Cancer. 43:617–623. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Avery-Kiejda KA, Zhang XD, Adams LJ, Scott
RJ, Vojtesek B, Lane DP and Hersey P: Small molecular weight
variants of p53 are expressed in human melanoma cells and are
induced by the DNA-damaging agent cisplatin. Clin Cancer Res.
14:1659–1668. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nutthasirikul N, Limpaiboon T, Leelayuwat
C, Patrakitkomjorn S and Jearanaikoon P: Ratio disruption of the
133p53 and TAp53 isoform equilibrium correlates with poor clinical
outcome in intrahepatic cholangiocarcinoma. Int J Oncol.
42:1181–1188. 2013.PubMed/NCBI
|
|
27
|
Aoubala M, Murray-Zmijewski F, Khoury MP,
Fernandes K, Perrier S, Bernard H, Prats AC, Lane DP and Bourdon
JC: p53 directly transactivates Δ133p53α, regulating cell fate
outcome in response to DNA damage. Cell Death Differ. 18:248–258.
2011. View Article : Google Scholar :
|
|
28
|
Hahnvajanawong C, Chaiyagool J, Seubwai W,
Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugk hem A and
Tassaneeyakul W: Orotate phosphoribosyl transferase mRNA expression
and the response of cholangiocarcinoma to 5-fluorouracil. World J
Gastroenterol. 18:3955–3961. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tepsiri N, Chaturat L, Sripa B, Namwat W,
Wongkham S, Bhudhisawasdi V and Tassaneeyakul W: Drug sensitivity
and drug resistance profiles of human intrahepatic
cholangiocarcinoma cell lines. World J Gastroenterol. 11:2748–2753.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thanasai J, Limpaiboon T, Jearanaikoon P,
Sripa B, Pairojkul C, Tantimavanich S and Miwa M: Effects of
thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil
sensitivity in cholangiocarcinoma. World J Gastroenterol.
16:1631–1638. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Voigt W: Sulforhodamine B assay and
chemosensitivity. Methods Mol Med. 110:39–48. 2005.PubMed/NCBI
|
|
32
|
Wattanawongdon W, Hahnvajanawong C, Namwat
N, Kanchanawat S, Boonmars T, Jearanaikoon P, Leelayuwat C,
Techasen A and Seubwai W: Establishment and characterization of
gemcitabine-resistant human cholangiocarcinoma cell lines with
multidrug resistance and enhanced invasiveness. Int J Oncol.
47:398–410. 2015.PubMed/NCBI
|
|
33
|
Nakano Y, Naoe T, Kiyoi H, Kitamura K,
Minami S, Miyawaki S, Asou N, Kuriyama K, Kusumoto S, Shimazaki C,
et al: Prognostic value of p53 gene mutations and the product
expression in de novo acute myeloid leukemia. Eur J Haematol.
65:23–31. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Albaric O, Bret L, Amardeihl M and
Delverdier M: Immunohistochemical expression of p53 in animal
tumors: A methodological study using four anti-human p53
antibodies. Histol Histopathol. 16:113–121. 2001.PubMed/NCBI
|
|
35
|
Limpaiboon T, Sripa B, Wongkham S,
Bhudhisawasdi V, Chau-in S and Teerajetgul Y: Anti-p53 antibodies
and p53 protein expression in cholangiocarcinoma.
Hepatogastroenterology. 51:25–28. 2004.PubMed/NCBI
|
|
36
|
Ong CK, Subimerb C, Pairojkul C, Wongkham
S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, et
al: Exome sequencing of liver fluke-associated cholangiocarcinoma.
Nat Genet. 44:690–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liang JT, Huang KC, Cheng YM, Hsu HC,
Cheng AL, Hsu CH, Yeh KH, Wang SM and Chang KJ: P53 overexpression
predicts poor chemosensitivity to high-dose 5-fluorouracil plus
leucovorin chemotherapy for stage IV colorectal cancers after
palliative bowel resection. Int J Cancer. 97:451–457. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Elsaleh H, Powell B, McCaul K, Grieu F,
Grant R, Joseph D and Iacopetta B: P53 alteration and
microsatellite instability have predictive value for survival
benefit from chemotherapy in stage III colorectal carcinoma. Clin
Cancer Res. 7:1343–1349. 2001.PubMed/NCBI
|
|
39
|
Kaeser MD, Pebernard S and Iggo RD:
Regulation of p53 stability and function in HCT116 colon cancer
cells. J Biol Chem. 279:7598–7605. 2004. View Article : Google Scholar
|
|
40
|
Reles A, Wen WH, Schmider A, Gee C,
Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C,
Schönborn I, et al: Correlation of p53 mutations with resistance to
platinum-based chemotherapy and shortened survival in ovarian
cancer. Clin Cancer Res. 7:2984–2997. 2001.PubMed/NCBI
|
|
41
|
Longley DB, Boyer J, Allen WL, Latif T,
Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP and
Johnston PG: The role of thymidylate synthase induction in
modulating p53-regulated gene expression in response to 5-
fluorouracil and antifolates. Cancer Res. 62:2644–2649.
2002.PubMed/NCBI
|
|
42
|
Goldschneider D, Blanc E, Raguénez G,
Barrois M, Legrand A, Le Roux G, Haddada H, Bénard J and Douc-Rasy
S: Differential response of p53 target genes to p73 overexpression
in SH-SY5Y neuroblastoma cell line. J Cell Sci. 117:293–301. 2004.
View Article : Google Scholar
|
|
43
|
Fang L, Lee SW and Aaronson SA:
Comparative analysis of p73 and p53 regulation and effector
functions. J Cell Biol. 147:823–830. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fulco M, Costanzo A, Merlo P, Mangiacasale
R, Strano S, Blandino G, Balsano C, Lavia P and Levrero M: p73 is
regulated by phosphorylation at the G2/M transition. J Biol Chem.
278:49196–49202. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhu J, Jiang J, Zhou W and Chen X: The
potential tumor suppressor p73 differentially regulates cellular
p53 target genes. Cancer Res. 58:5061–5065. 1998.PubMed/NCBI
|
|
46
|
He Y, Fan S, Jiang Y, Chen J, Li Z, Zhou P
and Zhou Y: Effect of exogenous p73 gene on chemosensitivity of
wild-type p53 human lung adenocarcinoma cell A549. Zhongguo Fei Ai
Za Zhi. 7:331–335. 2004.(In Chinese). PubMed/NCBI
|
|
47
|
He Y, Fan SZ, Jiang YG, Chen JM, Li ZP,
Zhou P and Zhou YG: Effect of p73 gene on chemosensitivity of human
lung adenocarcinoma cells H1299. Ai Zheng. 23:645–649. 2004.(In
Chinese). PubMed/NCBI
|
|
48
|
Adamsen BL, Kravik KL, Clausen OP and De
Angelis PM: Apoptosis, cell cycle progression and gene expression
in TP53-depleted HCT116 colon cancer cells in response to
short-term 5- fluorouracil treatment. Int J Oncol. 31:1491–1500.
2007.PubMed/NCBI
|
|
49
|
Guo X, Goessl E, Jin G, Collie-Duguid ES,
Cassidy J, Wang W and O'Brien V: Cell cycle perturbation and
acquired 5-fluorouracil chemoresistance. Anticancer Res. 28A:9–14.
2008.
|
|
50
|
Levrero M, De Laurenzi V, Costanzo A, Gong
J, Wang JY and Melino G: The p53/p63/p73 family of transcription
factors: Overlapping and distinct functions. J Cell Sci.
113:1661–1670. 2000.PubMed/NCBI
|
|
51
|
Jha AK, Nikbakht M, Jain V, Sehgal A,
Capalash N and Kaur J: Promoter hypermethylation of p73 and p53
genes in cervical cancer patients among north Indian population.
Mol Biol Rep. 39:9145–9157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang YL, Guo XR, Shen DH, Cheng YX, Liang
XD, Chen YX and Wang Y: Expression and promotor methylation of p73
gene in ovarian epithelial tumors. Zhonghua Bing Li Xue Za Zhi.
41:33–38. 2012.PubMed/NCBI
|
|
53
|
House MG, Wistuba II, Argani P, Guo M,
Schulick RD, Hruban RH, Herman JG and Maitra A: Progression of gene
hypermethylation in gallstone disease leading to gallbladder
cancer. Ann Surg Oncol. 10:882–889. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kawano S, Miller CW, Gombart AF, Bartram
CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E and Koeffler
HP: Loss of p73 gene expression in leukemias/lymphomas due to
hypermethylation. Blood. 94:1113–1120. 1999.PubMed/NCBI
|
|
55
|
Yang B, House MG, Guo M, Herman JG and
Clark DP: Promoter methylation profiles of tumor suppressor genes
in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol.
18:412–420. 2005. View Article : Google Scholar
|
